ADM Earnings Beat Hard - But the Dividend and Valuation Tell a Different Story

Archer-Daniels-Midland reported second-quarter 2026 results before market open today that will have sell-side analysts scrambling to update their models. GAAP diluted EPS came in at $1.87, compared to a consensus estimate of $1.26 - a 48% beat. Revenue hit $22.68 billion versus an expected $19.92 billion. Adjusted net earnings were $895 million. Management also raised full-year 2026 adjusted EPS guidance to a range of $4.15 to $4.70.

The numbers are real. The recovery is real. But I don't think the headline captures what the rest of the picture looks like from an income and risk/reward point of view.

The earnings recovery - what changed

ADM's second-quarter performance is dramatic when you step back and look at the prior-year comparison. Q2 2025 EPS was $0.45. Q2 2026 is $1.87 - a four-fold increase. That jump is not a function of operational miracle. It's a function of where you're coming from.

Last year's second quarter was decimated by the fallout from ADM's $780 million restatement related to its prior sustainability accounting scandal. The earnings base was broken, which is why the beat looks so large in percentage terms. The more useful comparison is against Q1 2026, where ADM reported $0.71 EPS and also raised guidance. The trajectory from $0.71 in Q1 to $1.87 in Q2 suggests genuine margin normalization, not just a statistical rebound.

Segment-level dynamics matter here. Q1 showed that Carbohydrate Solutions and Nutrition - ADM's higher-margin, more defensible businesses - offset continued weakness in Ag Services & Oilseeds, which is the cyclical commodity-crushing and merchandising side of the business. The company's $103 million Decatur modernization plan is specifically designed to tilt the mix further toward those higher-margin operations. If Q2 followed a similar pattern, the earnings quality is better than the headline suggests.

The payout ratio is the first thing that makes me pause

Here's where the story gets uncomfortable. ADM's trailing-twelve-month payout ratio sits at 91%. That number is distorted by the earnings collapse in the second half of the prior year - when EPS cratered but the dividend didn't - so the true forward payout is lower. If full-year 2026 adjusted EPS lands near the midpoint of the new guidance range, around $4.43, and the annual dividend holds at roughly $2.06, the forward payout ratio would be closer to 46%.

That is a much healthier number. But the 91% trailing figure tells you something important: ADM has cut its dividend exactly zero times in 59 years, even when earnings went through the floor. That discipline is admirable, but it also means the company will prioritize the payout over balance sheet comfort when times get rough. For the dividend growth investor, that's a double-edged sword. You get safety, but you also get a company that won't blink when margins compress.

The 33 consecutive years of dividend increases and the 32-year streak of consecutive growth are impressive credentials. The current yield of 2.63% is not a screaming entry point, but it's not a yield-chasing trap either. It sits in the moderate zone of the equity yield curve - where the compounding comes from dividend growth, not current income.

The valuation premium to Bunge is the real question

This is where I want to slow down and stay with one comparison because it changes how you frame the opportunity. ADM trades at 34.8 times trailing earnings. Bunge - its closest pure-play peer in the agricultural processing space - trades at 20.1 times. ADM's EV/EBITDA multiple is 18.9x versus Bunge's 11.5x.

That's not a small gap. ADM is trading at a 73% premium to Bunge on a P/E basis. You can argue that ADM's Nutrition and Carbohydrate Solutions businesses justify the premium - they are stickier, less commodity-exposed, and higher-margin than the crush-and-merchandise model that dominates Bunge's operations. But a 73% premium means the market is already pricing in years of outperformance.

Tyson Foods, another food-processing peer, trades at 46.3x earnings, so ADM is not the most expensive food processor in the group. But Tyson has structural margin issues from its livestock-integration model that don't apply to ADM. The more honest peer comparison is Bunge, and on that basis, ADM's valuation is stretched.

The balance sheet checks out - for now

ADM's debt-to-equity ratio stands at 40.4%, total debt is $32.5 billion, and the company carried $591 million in cash. Net debt after adjusting for cash and other factors comes to $8.7 billion. Free cash flow over the trailing twelve months was $4.8 billion - an enormous improvement, up 2,059% year over year, though again, that comparison is against a prior-year trough.

On a forward basis, free cash flow can comfortably support the current dividend. Even if we use the conservative end of the EPS guidance range at $4.15, that's roughly $1.8 billion in net earnings annualized. With $4.8 billion in trailing free cash flow - which normalizes higher than net earnings due to depreciation and working cycle dynamics - the dividend coverage is adequate. The company isn't living on the edge.

Capital spending is projected at $1.3 billion to $1.5 billion for 2026, which is manageable and reflects the ongoing shift toward higher-margin Nutrition capacity rather than massive commodity-infrastructure buildouts.

The inflation regime and ADM's pricing power

I believe inflation is likely to remain more persistent than the market wants to admit, and that structural thesis tilts the opportunity set toward companies that can raise prices without losing customers. ADM is one of those companies - but with an important caveat.

The Nutrition and Carbohydrate Solutions segments have genuine pricing power. Food manufacturers don't switch sweetener and ingredient suppliers on a whim. These are mission-critical inputs in complex formulations. When ADM raises prices, customers absorb them because the alternative is re-engineering their products.

The Ag Services & Oilseeds segment is different. It's a toll-road business where margins are driven by crush spreads and logistics efficiency, not pricing discretion. ADM doesn't set soybean meal prices. The market does. That part of the business is a real-economy play, but it's not an inflation-hedge play.

So ADM passes the pricing power test on roughly half its revenue base. That's good enough to support dividend growth over time, but it's not the kind of absolute pricing power you find in oligopoly industrial or energy names where the entire revenue stream is protected.

The entry problem

ADM stock is up 35.8% year-to-date. It's trading at $78, roughly 88% of its 52-week high of $88.46. The stock is down just 1.5% today despite the strong earnings, which suggests the move may have already been front-run.

The equity yield curve framework tells me that the sweet spot for dividend growth investors is moderate yields with strong growth potential - and you get the best risk/reward when you buy those businesses when they're out of favor, not after they've rallied 36% in a year. ADM's yield of 2.6% and its premium valuation to peers mean the setup is no longer asymmetric.

I don't think ADM is a terrible investment. It's a quality business with a durable payout, improving segment mix, and 59 years of dividend integrity. But I also don't think the risk/reward is compelling at this price. The earnings beat confirms what the stock has been telling you for months: the recovery is underway. The question is whether you're being paid enough to participate in the next leg.

The bottom line

ADM's Q2 results are solid, the guidance raise is real, and the dividend is safe. Those are not empty claims - they're supported by the numbers. But the stock has already rewarded investors handsomely for recognizing the turn. A 34.8x P/E, a 91% trailing payout ratio (even if it's a base-effect distortion), and a 73% valuation premium to Bunge mean the margin for error is thin.

From an income and risk/reward point of view, ADM belongs in a watch list right now, not a buy list. If the stock pulls back toward $65 - where the yield would stretch above 3%, the P/E would compress into the low 20s, and the premium to Bunge would narrow - it would become an interesting entry for the income-growth sleeve. At $78, the company deserves respect but not conviction.